Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Autores
Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; Bagur, Alicia Cristina; Oliveri, María Beatriz; Zanchetta, M. B.; Farias, V.; Maffei, L.; Premrou, V.; Mansur, J. L.; larroude, M. S.; Sarli, M. A.; Rey, P.; Ulla, M. R.; Pavlove, M. M.; Karlsbrum, S.; Brance, María Lorena
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina
Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina
Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina
Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina
Fil: Farias, V.. Universidad del Salvador; Argentina
Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina
Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina
Fil: Sarli, M. A.. Universidad del Salvador; Argentina
Fil: Rey, P.. Universidad del Salvador; Argentina
Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina
Fil: Pavlove, M. M.. Hospital Durand; Argentina
Fil: Karlsbrum, S.. Hospital Durand; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina
Materia
DENOSUMAB
BONE MINERAL DENSITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/55323

id CONICETDig_52887b8b5b4a7ed59d84d4e29c519ceb
oai_identifier_str oai:ri.conicet.gov.ar:11336/55323
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisSánchez, ArielBrun, Lucas Ricardo MartínSalerni, H.Costanzo, P. R.Gonzalez, D.Bagur, Alicia CristinaOliveri, María BeatrizZanchetta, M. B.Farias, V.Maffei, L.Premrou, V.Mansur, J. L.larroude, M. S.Sarli, M. A.Rey, P.Ulla, M. R.Pavlove, M. M.Karlsbrum, S.Brance, María LorenaDENOSUMABBONE MINERAL DENSITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Gonzalez, D.. Mautalen Salud E Investigación; ArgentinaFil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; ArgentinaFil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; ArgentinaFil: Zanchetta, M. B.. Universidad del Salvador; ArgentinaFil: Farias, V.. Universidad del Salvador; ArgentinaFil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; ArgentinaFil: larroude, M. S.. Cesar Milstein Hospital; ArgentinaFil: Sarli, M. A.. Universidad del Salvador; ArgentinaFil: Rey, P.. Universidad del Salvador; ArgentinaFil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; ArgentinaFil: Pavlove, M. M.. Hospital Durand; ArgentinaFil: Karlsbrum, S.. Hospital Durand; ArgentinaFil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; ArgentinaHindawi Limited2016-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/55323Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-62042-0064CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:13Zoai:ri.conicet.gov.ar:11336/55323instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:13.444CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
spellingShingle Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
Sánchez, Ariel
DENOSUMAB
BONE MINERAL DENSITY
title_short Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_fullStr Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full_unstemmed Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_sort Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
dc.creator.none.fl_str_mv Sánchez, Ariel
Brun, Lucas Ricardo Martín
Salerni, H.
Costanzo, P. R.
Gonzalez, D.
Bagur, Alicia Cristina
Oliveri, María Beatriz
Zanchetta, M. B.
Farias, V.
Maffei, L.
Premrou, V.
Mansur, J. L.
larroude, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, María Lorena
author Sánchez, Ariel
author_facet Sánchez, Ariel
Brun, Lucas Ricardo Martín
Salerni, H.
Costanzo, P. R.
Gonzalez, D.
Bagur, Alicia Cristina
Oliveri, María Beatriz
Zanchetta, M. B.
Farias, V.
Maffei, L.
Premrou, V.
Mansur, J. L.
larroude, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, María Lorena
author_role author
author2 Brun, Lucas Ricardo Martín
Salerni, H.
Costanzo, P. R.
Gonzalez, D.
Bagur, Alicia Cristina
Oliveri, María Beatriz
Zanchetta, M. B.
Farias, V.
Maffei, L.
Premrou, V.
Mansur, J. L.
larroude, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, María Lorena
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv DENOSUMAB
BONE MINERAL DENSITY
topic DENOSUMAB
BONE MINERAL DENSITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina
Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina
Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina
Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina
Fil: Farias, V.. Universidad del Salvador; Argentina
Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina
Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina
Fil: Sarli, M. A.. Universidad del Salvador; Argentina
Fil: Rey, P.. Universidad del Salvador; Argentina
Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina
Fil: Pavlove, M. M.. Hospital Durand; Argentina
Fil: Karlsbrum, S.. Hospital Durand; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina
description The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
publishDate 2016
dc.date.none.fl_str_mv 2016-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/55323
Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6
2042-0064
CONICET Digital
CONICET
url http://hdl.handle.net/11336/55323
identifier_str_mv Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6
2042-0064
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959
info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Hindawi Limited
publisher.none.fl_str_mv Hindawi Limited
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269209399132160
score 13.13397